Skip to main
IGC
IGC logo

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc is positioned favorably due to its ongoing development of investigational drug assets targeting Alzheimer's disease, which have shown potential effectiveness in addressing key hallmarks of the condition. The company's current valuation appears attractive, supported by a net present value analysis indicating significant upside potential from its current share price. Additionally, the anticipated release of positive data from ongoing studies is expected to act as a catalyst for further interest and investment in the stock.

Bears say

IGC Pharma Inc. reported a net loss of $1.6 million, resulting in earnings per share (EPS) of $(0.02), which aligns with prior estimates but underscores ongoing financial challenges. The company faces considerable risks, including balance sheet and liquidity concerns, potential failures in clinical trials for its investigational drug assets, and challenges in obtaining regulatory approvals and commercialization. Additionally, external factors such as macroeconomic changes and competition further complicate its financial outlook, limiting investor confidence in the stock’s future performance.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.